Other antibodies against TGFb are in early stage development; Sanofi-Aventis SAR439459 is in phase I/II with a single dose ascending study underway in adults with OI (https://www.sanofistudies.com/us/en/listing/295191/single-ascending-dose-study-of-sar439459-in-adults-with-osteogenesis-imperfecta-oi/). The gene discussed is TGFB1; the disease is osteogenesis imperfecta.